Key result
G6PD inhibition attenuates abdominal aortic aneurysm progression in preclinical models by reducing neutrophil extracellular traps.
Why the study?
Does G6PD inhibition reduce NET formation and attenuate abdominal aortic aneurysm progression in preclinical models?
Does G6PD inhibition reduce NET formation and attenuate abdominal aortic aneurysm progression in preclinical models?
Inhibition of G6PD suppresses pentose phosphate pathway activity and reduces neutrophil extracellular trap formation, offering a potential therapeutic target for attenuating abdominal aortic aneurysm progression.
Introduction: Neutrophil extracellular traps (NETs) have emerged as critical contributors to the pathogenesis of abdominal aortic aneurysm (AAA). Excessive NET formation exacerbates inflammatory responses, and metabolic reprogramming of neutrophils may underlie the augmented NET production observed in AAA. This study investigates the impact of altered neutrophil energy metabolism—specifically via the pentose phosphate pathway (PPP)—on NET formation in AAA. Methods: Peripheral blood neutrophils were isolated from healthy volunteers (n = 4) and AAA patients (n = 4) to conduct comprehensive central carbon metabolism profiling and identify pertinent metabolic alterations. An AAA model was established in 8-week-old ApoE-/- mice using angiotensin II (AngII) infusion (1000 ng/kg/min). The animals were divided into a control group and various intervention groups (n = 20 per group) to evaluate AAA progression and NET formation. Additionally, in vitro experiments were performed using neutrophils from healthy donors to assess NET production and reactive oxygen species (ROS) release under different treatment conditions. Results: Metabolomic analysis revealed a significant upregulation of the PPP in neutrophils derived from AAA patients. The key enzyme of this pathway, glucose-6-phosphate dehydrogenase (G6PD), was markedly elevated in the serum of AAA patients as confirmed by ELISA, and its levels showed a positive correlation with the NET marker dsDNA concentration (P = 0.0026). In the murine model, administration of a G6PD inhibitor (G6PDi-1) led to reduced AAA rupture rates and diminished aneurysmal diameters, concomitant with a notable decrease in NET formation. In vitro, AngII stimulation enhanced NET formation and ROS production in neutrophils, effects that were effectively attenuated by G6PDi-1. Conclusion: In conclusion, this research indicate that neutrophils in AAA undergo metabolic reprogramming, characterized by upregulated PPP activity, which in turn promotes excessive NET formation and disease progression. Inhibition of G6PD effectively suppresses PPP activity, reduces NET formation, and attenuates AAA development, highlighting G6PD as a promising therapeutic target for AAA management.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2025) studied Abdominal aortic aneurysm (n=8). G6PD inhibitor (G6PDi-1) vs. Control group was evaluated on AAA rupture rates, aneurysmal diameters, and NET formation. Inhibition of G6PD effectively suppressed pentose phosphate pathway activity, reduced neutrophil extracellular trap formation, and attenuated abdominal aortic aneurysm development in a murine model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: